Skip to content

Asarina Pharma over-allotment option fully exercised as stabilization period of share offering ends

Stockholm – October 24, 2018: Erik Penser Bank (“EPB”) has been the stabilization manager for Asarina Pharma AB (publ) in connection with its recent offering of 6,800,000 new shares ("the Offer"), and the listing of the Company’s shares on Nasdaq First North. EPB hereby announces the stabilization period of thirty calendar days following the listing of the Company's shares ended 23 October, with no stabilization transactions having been carried out.

In its capacity as stabilization manager, EPB had the authority to carry out transactions aimed at supporting the price of the Asarina share at a higher level than would otherwise have prevailed in the market, although not at a price higher than the subscription price in the Offer.

Furthermore, Asarina Pharma has issued an option to EPB to subscribe to 350,000 newly issued shares in the Company (the ”Over-allotment option”), corresponding to no more than 5.1 percent of the number of newly issued shares in the Offer, to cover any possible oversubscription in the Offer. The price of the newly issued shares in the Over-allotment option equals the price in the Offer, SEK 21 per share. EPB announces that the Over-allotment option of 350,000 shares has been fully exercised.

The Company will thus be provided with an additional SEK 7.35M, which means that the Company has received a total of SEK 150.2M, before transaction costs, through the Offer and the Over-allotment option. After registration of the new shares issued under the Over-allotment option, the number of shares and votes in the Company will amount to 16,037,218.

For further information, please contact:

Peter Nordkild, CEO, Asarina Pharma AB

Phone: +45 25 47 16 46

E-mail: peter.nordkild@asarinapharma.com

Erik Penser Bank AB is the Company’s Certified Adviser.

About Asarina Pharma AB

We are a Swedish biotech company developing Sepranolone, the world’s first dedicated treatment for premenstrual dysphoric disorder (PMDD) and other menstrual-related conditions. Our product pipeline is built on over 40 years’ research into menstrual-related disorders like PMDD and menstrual migraine. With our new family of GAMSA compounds (GABAAModulating Steroid Antagonists), we aim to deliver a new generation of efficacious and safe drugs for still widely untreated conditions, thereby becoming a leading Women’s Health company.

Release